| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Name | Posaconazole |
| CAS | 171228-49-2 |
| MF | C37H42F2N8O4 |
| MW | 700.777 |
| EINECS | 682-747-8 |
| Appearance | white Powder |
| Categories | API;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals |
| Fp | 9ºC |
| Storage temp. | -20°C Freezer |
Posaconazole, launched in the UK, is the newest member of the a zole class of antifungal agents to reach the market. It is indicated for the treatment and prophylaxis of a range of invasive fungal infections, including aspergillosis,fusariosis, chromoblastomycosis, mycetoma, and coccidiomycosis in patients who are refractory to, or intolerant of, standard therapy with amphotericin B and/or itracona zole. In the US, it is approved for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age who are at high risk of developing these infections due to being severely immunocompromised. Additionally, it is approved for the treatment of oropharyngeal candidiasis. Posacona zole has an expanded spectrum of activity over other members of the a zole antifungals. In addition to potent activity against refractory cases of aspergillosis and flucona zole-resistant Candida, it demonstrates activity against Zygomycetes.
Posacona zole use to treat:
Invasive aspergillosis,Fusarium infection,Chromoblastomycosis and mycetoma,Coccidioidomycosis,Oropharyngeal candidosis
Prophylaxis of invasive fungal infections in patients at serious risk
With the exception of oropharyngeal candidosis and prophylaxis, use is presently restricted to patients with disease that is refractory to other antifungal drugs, or who are intolerant to them.
Posacona zole, launched in the UK, is the newest member of the a zole class of antifungal agents to reach the market. It is indicated for the treatment and prophylaxis of a range of invasive fungal infections, including aspergillosis,fusariosis, chromoblastomycosis, mycetoma, and coccidiomycosis in patients who are refractory to, or intolerant of, standard therapy with amphotericin B and/or itracona zole. In the US, it is approved for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age who are at high risk of developing these infections due to being severely immunocompromised. Additionally, it is approved for the treatment of oropharyngeal candidiasis. Posacona zole has an expanded spectrum of activity over other members of the a zole antifungals. In addition to potent activity against refractory cases of aspergillosis and flucona zole-resistant Candida, it demonstrates activity against Zygomycetes.
){kind=link}